knowledge -WSS

knowledge

author：comprehensive 2025-09-06 02:10:26 - browse：3279

When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.

For more on what we cover, here’s where you can read Frank’s work; here’s more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Supreme Court strikes down use of affirmative action
Next article： First Opinion Podcast: How to protect health care in times of war

WSS

Wegovy improves function in certain heart failure patients

CDC recommends rationing of RSV shot due to shortages

California store owner shot dead in dispute over displaying Pride flag: Police

Emergency medicine has repudiated 'excited delirium.' Now what?

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Study: Spinal cord stimulation helps patients with paralysis walk again

explore

knowledge

hotspot

Drug repurposing or repositioning? The language matters

CDC recommends rationing of RSV shot due to shortages

Jerome Adams on the need for new antivirals for Covid

Wegovy improves function in certain heart failure patients

Cancer drug shortages should be causing more outrage

Intellia plays down concerns on accidental germline transmission

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Dobbs anniversary: the lost opportunity of abortion as health care

Maker of FluMist seeks to allow at

leisure time

Diversifying clinical trials isn't enough to close racial gaps: study

FDA has safety concerns on CRISPR

Intellia plays down concerns on accidental germline transmission

The pink breast cancer awareness ribbon needs a redesign

Traditional Chinese medicine benefits explored in new JAMA study

Senate panel to vote on hospitals, PBMs, prisoner care

leisure time

focus

hotspot

hotspot